LEADING PRODUCT CANDIDATE
Bluejay Diagnostics is pleased to present Symphony, a near-patient biomarker detection platform. Symphony aims to help improve healthcare outcomes by providing quantitative clinical chemistry results vital for triage and acute care..
Symphony is an innovative implementation of the traditionally reliable ELISA methodology combined with modern advances in nanotechnology. The unique design features a combination of microfluidics and interrupted fluid dynamics to offer fast, simple, safe, and highly sensitive biomarker detection.
*Not FDA cleared. For research use only
PRODUCTS IN DEVELOPMENT
Symphony is an automated diagnostic system, consisting of a fluorescence immuno-analyzer which uses a single-use diagnostic test cartridge with reagents integrated in the cartridge. Symphony utilizes a ‘sample-to-result’ format, which means that once a specimen is taken from the patient, it is placed in the cartridge and then the cartridge is placed inside the analyzer where the test is run without further technician intervention or additional reagent. This reduces test complexity and eliminates the need for highly trained and expensive laboratory technicians to run the tests.
Our platform is designed to enable simple, rapid, and cost-effective analysis from a single clinical sample, which will allow LTACs, hospitals and clinics that traditionally could not afford more expensive or complex diagnostic testing platforms to modernize their laboratory testing and provide better patient testing at an affordable cost in time sensitive, life threatening situations.
Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America
ACTON, Mass./WEST WARWICK, R.I., February 16, 2023 – Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”), and Blood Centers of America (BCA) today announced that they have executed a collaborative agreement to develop commercial relationships to serve unmet needs by utilizing the SymphonyTM Platform in the blood and hospital markets.
Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a pre-revenue medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced financial results for the quarter ended March 31, 2022.
Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that the FDA has agreed to consider Bluejay’s plan to pursue a De Novo submission for the Symphony IL-6 Test